GSK-114

• CAT Number: I007062
• CAS Number: 1301761-96-5
• Molecular Formula: C19H23N5O4S
• Molecular Weight: 417.48
• Purity: ≥95%
• Synonyms: 3-[(6,7-dimethoxyquinazolin-4-yl)amino]-4-(dimethylamino)-N-methylbenzenesulfonamide
• InChI: InChI=1S/C19H23N5O4S/c1-20-29(25,26)12-6-7-16(24(2)3)15(8-12)23-19-13-9-17(27-4)18(28-5)10-14(13)21-11-22-19/h6-11,20H,1-5H3,(H,21,22,23)
• InChIKey: YUSROMRPOFFTMX-UHFFFAOYSA-N
• SMILES: CNS(=O)(=O)C1=CC(=C(C=C1)N(C)C)NC2=NC=NC3=CC(=C(C=C32)OC)OC

GSK-114 (Cat No.: I007062) is a potent, selective HIV-1 maturation inhibitor developed by GlaxoSmithKline for antiviral research. It targets the Gag protein cleavage process, disrupting viral capsid maturation and producing non-infectious viral particles. Unlike reverse transcriptase or protease inhibitors, GSK-114 interferes with a late stage of the viral life cycle, offering a distinct therapeutic approach. It has been investigated for its ability to combat drug-resistant HIV strains. GSK-114 remains an important research tool for studying HIV maturation, replication, and antiretroviral drug discovery.

Reference

[1]. Lawhorn BG, et al. GSK114: A selective inhibitor for elucidating the biological role of TNNI3K. Bioorg Med Chem Lett. 2016;26(14):3355-3358.
[Content Brief]

[2]. Asquith CRM, et al. New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I-Interacting Kinase (TNNi3K). Molecules. 2020;25(7):1697. Published 2020 Apr 7.
[Content Brief]